Aliskiren therapy will have minimal effect on intracellular renin of renin-producing cells.
Campbell
Duncan John
DJ
D000577:Amides / Q000097:blood / Q000494:pharmacology*; D000808:Angiotensinogen / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000959:Antihypertensive Agents / Q000097:blood / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005576:Colforsin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005650:Fumarates / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D007606:Juxtaglomerular Apparatus / Q000187:drug effects / Q000378:metabolism*; D007946:Leukemia, Mast-Cell / Q000378:metabolism* / Q000473:pathology; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D055647:Rats, Transgenic; D012083:Renin / Q000235:genetics / Q000378:metabolism*
D000577:Amides; D000959:Antihypertensive Agents; D005650:Fumarates; D000808:Angiotensinogen; D005576:Colforsin; C446481:aliskiren; D012083:Renin